IL256424A - שיטות לטיפול בהפרעות אוטואימוניות ואלואימוניות - Google Patents

שיטות לטיפול בהפרעות אוטואימוניות ואלואימוניות

Info

Publication number
IL256424A
IL256424A IL256424A IL25642417A IL256424A IL 256424 A IL256424 A IL 256424A IL 256424 A IL256424 A IL 256424A IL 25642417 A IL25642417 A IL 25642417A IL 256424 A IL256424 A IL 256424A
Authority
IL
Israel
Prior art keywords
methods
treating autoimmune
alloimmune disorders
alloimmune
disorders
Prior art date
Application number
IL256424A
Other languages
English (en)
Other versions
IL256424B2 (he
IL256424B1 (he
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of IL256424A publication Critical patent/IL256424A/he
Publication of IL256424B1 publication Critical patent/IL256424B1/he
Publication of IL256424B2 publication Critical patent/IL256424B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL256424A 2015-06-26 2016-06-23 שיטות לטיפול בהפרעות אוטואימוניות ואלואימוניות IL256424B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (3)

Publication Number Publication Date
IL256424A true IL256424A (he) 2018-02-28
IL256424B1 IL256424B1 (he) 2024-05-01
IL256424B2 IL256424B2 (he) 2024-09-01

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256424A IL256424B2 (he) 2015-06-26 2016-06-23 שיטות לטיפול בהפרעות אוטואימוניות ואלואימוניות

Country Status (12)

Country Link
US (2) US20180169240A1 (he)
EP (1) EP3313417A4 (he)
JP (1) JP6963509B2 (he)
KR (1) KR20180020296A (he)
CN (1) CN108348600A (he)
AU (2) AU2016282782A1 (he)
CA (1) CA2990662A1 (he)
EA (1) EA038567B1 (he)
HK (1) HK1254030A1 (he)
IL (1) IL256424B2 (he)
MX (2) MX2017016835A (he)
WO (1) WO2016210172A1 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
PL3448419T3 (pl) * 2016-04-29 2023-09-04 Pfizer Inc. Przeciwciała interferonu beta i ich zastosowania
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
US20240092889A1 (en) * 2019-10-16 2024-03-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
AU2009239437B2 (en) * 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
JP2012531418A (ja) * 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体タンパク質に結合する二重特異性抗体
EP2912065A4 (en) * 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
EP3313417A1 (en) 2018-05-02
IL256424B2 (he) 2024-09-01
AU2022215307A1 (en) 2022-09-08
CN108348600A (zh) 2018-07-31
EA201890106A1 (ru) 2018-05-31
US20180169240A1 (en) 2018-06-21
MX2023002021A (es) 2023-03-15
KR20180020296A (ko) 2018-02-27
JP6963509B2 (ja) 2021-11-10
IL256424B1 (he) 2024-05-01
HK1254030A1 (zh) 2019-07-12
AU2016282782A1 (en) 2018-01-18
WO2016210172A1 (en) 2016-12-29
MX2017016835A (es) 2018-08-01
US20220249664A1 (en) 2022-08-11
EA038567B1 (ru) 2021-09-15
BR112017027578A2 (pt) 2018-08-28
JP2018526330A (ja) 2018-09-13
EP3313417A4 (en) 2019-06-12
CA2990662A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
IL285151A (he) שיטות לטיפול בהפרעות קשורות ל– fgf21
HK1251455A1 (zh) 聚糖治療劑和治療方法
HRP20210526T8 (hr) Oksisteroli i postupci za njihovu uporabu
IL289976A (he) אוקסיסטירולים ושיטות לשימוש בהם
HK1255500A1 (zh) 氧固醇及其使用方法
HK1254030A1 (zh) 治療自身免疫病症和同種免疫病症的方法
HK1259294A1 (zh) 用於治療自身免疫疾病和癌症的組合物及方法
IL259861A (he) שיטות ותכשירים לטיפול בהפרעות הקשורות להתקפים
IL282482A (he) וריאנטים של פרוטוקסין–ii ושיטות לשימוש
IL282508A (he) וריאנטים של פרוטוקסין–ii ושיטות לשימוש
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
IL265568A (he) שיטות לטיפול בהרמת tim-3
EP3654965C0 (en) METHOD FOR TREATING MICROVASCULAR AUTOIMMUNE DISEASES
GB201503371D0 (en) Methods of screening and treatment
GB201522615D0 (en) Methods of screening and treatment
GB201505437D0 (en) Methods of screening and treatment
GB201503392D0 (en) Methods of screening and treatment
GB201421511D0 (en) Methods of screening and treatment